Clinical and Radiological Observations in a Case Series of 26 Patients with Fibrous Dysplasia

被引:0
作者
Malissa Dawn Thomsen
Lars Rejnmark
机构
[1] Aarhus University Hospital,Department of Endocrinology and Internal Medicine (MEA)
来源
Calcified Tissue International | 2014年 / 94卷
关键词
Bisphosphonate; Osteoclast; McCune–Albright syndrome; Focal bone lesion; Fibrous dysplasia;
D O I
暂无
中图分类号
学科分类号
摘要
Fibrous dysplasia (FD) is a rare disease caused by a sporadic postzygotic missense mutation that leads to abnormal fibroblast proliferation, defective osteoblast differentiation, and increased bone resorption. It may affect one or several bones. Both the mono-ostotic and polyostotic types may be associated with hyperfunctional endocrinopathies and hyperpigmentation of the skin (café-au-lait spots) in the so-called McCune–Albright syndrome (MAS). Due to its rarity, only a few case series are available, making it difficult for most clinicians to judge the severity of the disease. To improve our knowledge of FD, we reviewed all cases of FD treated at our department of endocrinology. Among 26 patients, 17 (65 %) had polyostotic FD, with four being diagnosed with MAS. Patients with polyostotic FD were diagnosed at an earlier age (median 13, range 0.5–64 years) than patients with the mono-ostotic form (median 21, 1–70 years). Craniofacial bones were affected in 80 % of cases, and 66 % complained of bone pain at the affected site, with no difference between patients with mono- and polyostotic FD. Two patients with mono-ostotic and three with polyostotic FD had cranial nerve impairments. Fourteen underwent, at least, one surgery, six (67 %) with mono-ostotic and eight (47 %) with polyostotic FD. Most received treatment with bisphosphonates, but therapy did not result in any clear relief of symptoms or radiological improvements. In conclusion, bone pain is common in patients with FD. The severity of the disease depends on affected bones as mono-ostotic may be as debilitating as polyostotic FD. In our case series, bisphosphonate treatment did not show clear beneficial effects.
引用
收藏
页码:384 / 395
页数:11
相关论文
共 246 条
  • [1] Chapurlat RD(2008)Fibrous dysplasia of bone and McCune–Albright syndrome Best Pract Res Clin Rheumatol 22 55-69
  • [2] Orcel P(2009)The nature of fibrous dysplasia Head Face Med 5 22-442
  • [3] Feller L(2003)Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression Bone 33 434-537
  • [4] Wood N(1990)Fibrous dysplasia Radiographics 10 519-177
  • [5] Khammissa R(2003)Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society J Pediatr Orthop B 12 155-242
  • [6] Lemmer J(2004)Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment Bone 35 235-202
  • [7] Raubenheimer E(2012)Pathophysiology and medical treatment of pain in fibrous dysplasia of bone Orphanet J Rare Dis 7 S3-1141
  • [8] Riminucci M(2009)Scoliosis and spine involvement in fibrous dysplasia of bone Eur Spine J 18 196-813
  • [9] Kuznetsov SA(2012)Mechanism of FGF23 processing in fibrous dysplasia J Bone Miner Res 27 1132-237
  • [10] Cherman N(2001)Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia J Bone Miner Res 16 806-1864